FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397136240> ?p ?o ?g. }

• W2397136240 endingPage "391" @default.
• W2397136240 startingPage "382" @default.
• W2397136240 abstract "We report our initial clinical experience with β -emitting (177)Lu-PSMA-I&T ((177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy) for systemic treatment of metastatic castration resistant prostate cancer.Patients with metastatic castration resistant prostate cancer who experienced treatment failure with chemotherapy and novel androgen receptor targeted therapy were treated for 8 weeks with up to 4 cycles of (177)Lu-PSMA-I&T. We report safety data, the antitumor response with prostate specific antigen decreases and the radiographic tumor response as well as the clinical outcome with changes in ECOG (Eastern Cooperative Oncology Group) performance status and pain severity.The first 3 patients were treated with a lower activity of 3.7 GBq in cycle 1. Due to a favorable safety profile the activity was increased to 7.4 GBq in 19 subsequent patients who completed a total of 40 cycles. With the higher activity no grade 3/4 toxicities were observed. The main nonhematological and hematological grade 1/2 toxicities were dry mouth in 7 patients (37%), anemia in 6 (32%) and thrombopenia in 5 (25%). The proportion of patients who achieved a maximum prostate specific antigen decrease of 30% or greater, 50% or greater and 90% or greater was 56%, 33% and 11%, respectively. Combined assessment of bone and soft tissue metastases showed complete remission in 5% of patients, stable disease in 63% and progressive disease in 32%. ECOG performance status improved or was stable in 74% of patients. Of men with bone pain 58% achieved complete resolution or reduced pain.Radioligand therapy with (177)Lu-PSMA-I&T appears to be safe and active in heavily pretreated patients with metastatic castration resistant prostate cancer." @default.
• W2397136240 created "2016-06-24" @default.
• W2397136240 creator A5000481071 @default.
• W2397136240 creator A5001283587 @default.
• W2397136240 creator A5002762582 @default.
• W2397136240 creator A5003688542 @default.
• W2397136240 creator A5030908792 @default.
• W2397136240 creator A5038906134 @default.
• W2397136240 creator A5044256035 @default.
• W2397136240 creator A5051959238 @default.
• W2397136240 creator A5055684567 @default.
• W2397136240 creator A5057421384 @default.
• W2397136240 creator A5064022467 @default.
• W2397136240 creator A5067456208 @default.
• W2397136240 creator A5067941796 @default.
• W2397136240 creator A5068315207 @default.
• W2397136240 date "2016-08-01" @default.
• W2397136240 modified "2023-10-18" @default.
• W2397136240 title "Systemic Radioligand Therapy with ¹⁷⁷ Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer" @default.
• W2397136240 cites W1140456871 @default.
• W2397136240 cites W1546799663 @default.
• W2397136240 cites W1942708746 @default.
• W2397136240 cites W2006508473 @default.
• W2397136240 cites W2016973566 @default.
• W2397136240 cites W2079633798 @default.
• W2397136240 cites W2090257199 @default.
• W2397136240 cites W2097512974 @default.
• W2397136240 cites W2105337740 @default.
• W2397136240 cites W2119391023 @default.
• W2397136240 cites W2134364976 @default.
• W2397136240 cites W2147136637 @default.
• W2397136240 cites W2155421560 @default.
• W2397136240 cites W2155847415 @default.
• W2397136240 cites W2163470211 @default.
• W2397136240 cites W2167331614 @default.
• W2397136240 cites W2168083201 @default.
• W2397136240 cites W2175765437 @default.
• W2397136240 cites W2326130899 @default.
• W2397136240 cites W2326657743 @default.
• W2397136240 cites W2415973042 @default.
• W2397136240 doi "https://doi.org/10.1016/j.juro.2016.02.2969" @default.
• W2397136240 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26964917" @default.
• W2397136240 hasPublicationYear "2016" @default.
• W2397136240 type Work @default.
• W2397136240 sameAs 2397136240 @default.
• W2397136240 citedByCount "155" @default.
• W2397136240 countsByYear W23971362402016 @default.
• W2397136240 countsByYear W23971362402017 @default.
• W2397136240 countsByYear W23971362402018 @default.
• W2397136240 countsByYear W23971362402019 @default.
• W2397136240 countsByYear W23971362402020 @default.
• W2397136240 countsByYear W23971362402021 @default.
• W2397136240 countsByYear W23971362402022 @default.
• W2397136240 countsByYear W23971362402023 @default.
• W2397136240 crossrefType "journal-article" @default.
• W2397136240 hasAuthorship W2397136240A5000481071 @default.
• W2397136240 hasAuthorship W2397136240A5001283587 @default.
• W2397136240 hasAuthorship W2397136240A5002762582 @default.
• W2397136240 hasAuthorship W2397136240A5003688542 @default.
• W2397136240 hasAuthorship W2397136240A5030908792 @default.
• W2397136240 hasAuthorship W2397136240A5038906134 @default.
• W2397136240 hasAuthorship W2397136240A5044256035 @default.
• W2397136240 hasAuthorship W2397136240A5051959238 @default.
• W2397136240 hasAuthorship W2397136240A5055684567 @default.
• W2397136240 hasAuthorship W2397136240A5057421384 @default.
• W2397136240 hasAuthorship W2397136240A5064022467 @default.
• W2397136240 hasAuthorship W2397136240A5067456208 @default.
• W2397136240 hasAuthorship W2397136240A5067941796 @default.
• W2397136240 hasAuthorship W2397136240A5068315207 @default.
• W2397136240 hasConcept C121608353 @default.
• W2397136240 hasConcept C126322002 @default.
• W2397136240 hasConcept C126894567 @default.
• W2397136240 hasConcept C143998085 @default.
• W2397136240 hasConcept C2776235491 @default.
• W2397136240 hasConcept C2776694085 @default.
• W2397136240 hasConcept C2777899217 @default.
• W2397136240 hasConcept C2778311097 @default.
• W2397136240 hasConcept C2780192828 @default.
• W2397136240 hasConcept C2781406297 @default.
• W2397136240 hasConcept C71924100 @default.
• W2397136240 hasConceptScore W2397136240C121608353 @default.
• W2397136240 hasConceptScore W2397136240C126322002 @default.
• W2397136240 hasConceptScore W2397136240C126894567 @default.
• W2397136240 hasConceptScore W2397136240C143998085 @default.
• W2397136240 hasConceptScore W2397136240C2776235491 @default.
• W2397136240 hasConceptScore W2397136240C2776694085 @default.
• W2397136240 hasConceptScore W2397136240C2777899217 @default.
• W2397136240 hasConceptScore W2397136240C2778311097 @default.
• W2397136240 hasConceptScore W2397136240C2780192828 @default.
• W2397136240 hasConceptScore W2397136240C2781406297 @default.
• W2397136240 hasConceptScore W2397136240C71924100 @default.
• W2397136240 hasIssue "2" @default.
• W2397136240 hasLocation W23971362401 @default.
• W2397136240 hasLocation W23971362402 @default.
• W2397136240 hasOpenAccess W2397136240 @default.
• W2397136240 hasPrimaryLocation W23971362401 @default.
• W2397136240 hasRelatedWork W1992657261 @default.
• W2397136240 hasRelatedWork W2038565121 @default.

• next